This page shows the publications co-authored by Deepak Bhatt and Rahul Aggarwal.
Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States. Circ Heart Fail. 2022 Mar; 15(3):e009099.
Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States. Prog Cardiovasc Dis. 2021 Sep-Oct; 68:97-98.
Generalizability of DAPA-CKD to the United States. Circ Cardiovasc Qual Outcomes. 2021 07; 14(7):e007875.
U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy. J Am Coll Cardiol. 2020 12 15; 76(24):2907-2910.
Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone. J Am Heart Assoc. 2022 Apr 05; 11(7):e025079.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.